miRNA-200a调控FOXC1增敏肺癌EGFR-TKI治疗的研究

发布时间：2018-04-22 23:39

本文选题：表皮生长因子受体酪氨酸激酶抑制剂 + miRNA-a　；参考：《南京医科大学学报(自然科学版)》2017年09期

【摘要】：目的 :探究miRNA-200a对非小细胞肺癌(non-small cell lung cancer,NSCLC)靶向治疗疗效的影响及其调控机制。方法:通过RT-PCR、Western blot等方法检测NSCLC细胞中miRNA-200a、FOXC1的表达量;四甲基偶氮唑盐(MTT)实验、细胞划痕实验、Transwell实验分别检测miRNA-200a、FOXC1对肺腺癌细胞生长、迁移、侵袭等生物学行为的影响;荧光素酶报告实验分析FOXC1与miRNA-200a的靶向关系。结果:高表达miRNA-200a抑制肺腺癌细胞的生长、上皮间质转化、迁移、侵袭,并且增加肺腺癌细胞对吉非替尼的敏感性。此外,敲低FOXC1同样可以抑制细胞生长,恢复肺腺癌细胞对吉非替尼敏感性。结论:上调miRNA-200a或下调FOXC1可以增强NSCLC细胞对吉非替尼的敏感性。为克服表皮生长因子受体酪氨酸激酶抑制剂治疗的耐药性提供了一种新的有效治疗方法。
[Abstract]:Aim: to investigate the effect of miRNA-200a on the therapeutic efficacy and regulatory mechanism of non-small cell lung cancer (NSCLC) in non-small cell lung cancer (NSCLC). Methods: the expression of miRNA-200aFXC1 in NSCLC cells was detected by RT-PCR- Western blot, and the effects of miRNA-200aFOXC1 on the growth, migration and invasion of lung adenocarcinoma cells were detected by MTT assay and cell scratch test respectively. Luciferase report was used to analyze the targeting relationship between FOXC1 and miRNA-200a. Results: overexpression of miRNA-200a inhibited the growth, epithelial interstitial transformation, migration and invasion of lung adenocarcinoma cells, and increased the sensitivity of lung adenocarcinoma cells to gefitinib. In addition, knockout FOXC1 can also inhibit cell growth and restore the sensitivity of lung adenocarcinoma cells to gefitinib. Conclusion: upregulation of miRNA-200a or down-regulation of FOXC1 can enhance the sensitivity of NSCLC cells to gefitinib. To overcome the epidermal growth factor receptor tyrosine kinase inhibitor drug resistance to provide a new and effective treatment.
【作者单位】：南京医科大学第一附属医院老年呼吸科;南京医科大学第一附属医院老年肾脏科;
【基金】：科技部国际科技合作专项(2014DFA31940) 国家自然科学基金(81572259) 江苏省干部保健课题(BJ15018)
【分类号】：R734.2

【相似文献】